Insider Transactions in Q4 2025 at Day One Biopharmaceuticals, Inc. (DAWN)
Insider Transaction List (Q4 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 25
2025
|
Jeremy Bender CHIEF EXECUTIVE OFFICER |
SELL
Bona fide gift
|
Indirect |
614,450
-49.59%
|
-
|
|
Nov 25
2025
|
Jeremy Bender CHIEF EXECUTIVE OFFICER |
BUY
Bona fide gift
|
Indirect |
600,000
+50.0%
|
-
|
|
Nov 17
2025
|
Lauren Merendino Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
3,726
-6.83%
|
$29,808
$8.91 P/Share
|
|
Nov 17
2025
|
Charles N York Ii COO and CFO |
SELL
Open market or private sale
|
Direct |
4,062
-1.36%
|
$32,496
$8.91 P/Share
|
|
Nov 17
2025
|
Adam Dubow Gen Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
4,319
-6.45%
|
$34,552
$8.91 P/Share
|
|
Nov 17
2025
|
Jeremy Bender CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
15,894
-8.23%
|
$127,152
$8.91 P/Share
|
|
Nov 15
2025
|
Lauren Merendino Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,536
+6.46%
|
-
|
|
Nov 15
2025
|
Charles N York Ii COO and CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
16,875
+1.41%
|
-
|
|
Nov 15
2025
|
Adam Dubow Gen Counsel & Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
12,087
+4.61%
|
-
|
|
Nov 15
2025
|
Jeremy Bender CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
31,694
+4.15%
|
-
|